deaths (OS)

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 2 1.0better0.35.0100 %
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 1.0better0.35.0100 %
relatlimab plus nivolumab vs. nivolumab alone 1 -

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 1.0better0.35.073 %

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 -